GLP-1 & compounded medication availability in Iowa (2026)
Iowa did something most states have not: it wrote the federal “essentially a copy” standard into its own administrative code, line by line. The practical effect for an Iowa patient is about paperwork, not access. The prescription behind a compounded GLP-1 has to spell out what is clinically different about it for you, because in Iowa a bare drug name on a script is, by rule, not enough.
What ships to Iowa: all ten lines
| Product line | Available in Iowa? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Dispensed against documentation meeting Iowa’s copy rule, cited below. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same documentation standard as the semaglutide line; national price. |
| NAD+ | Yes | 8–10 business days | No Iowa-specific condition attaches. |
| Sermorelin | Yes | 8–10 business days | Standard flow, no state add-ons. |
| Glutathione | No | N/A | Not offered through OrderlyMeds right now. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; federal record stated below. |
| TB-500 | Yes | 8–10 business days | Injectable; see the federal section under the table. |
| KPV | No | N/A | Outside our injectable-only peptide formulary. |
| Epitalon | Yes | 8–10 business days | Injectable; its federal facts are below. |
| MOTS-c | Yes | 8–10 business days | Injectable whose federal record stands apart, below. |
A No above is a real No, not a formatting gap. Iowa rows were last checked on November 16, 2026.
Research peptides in Iowa: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Iowa addresses can receive four of these five lines as compounded injectables, each filled on a patient-specific prescription: BPC-157, TB-500, Epitalon and MOTS-c. KPV ships nowhere: we compound these lines as injectables only. Each line’s federal record follows, per substance, present whether or not the line is available to you.
BPC-157 in Iowa
Reaches Iowa patients as a compounded injectable on a patient-specific prescription. Both federal facts below apply without an Iowa exception.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Iowa
Fills to Iowa addresses as a compounded injectable, patient-specific prescription in hand. Federal record next.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Iowa
Does not ship to Iowa or anywhere, because our peptide lines are injectables and KPV is not compounded that way for us.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Iowa
In the Iowa formulary as a compounded injectable on a patient-specific prescription; the federal section below is the one to read.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Iowa
Ships to Iowa as a compounded injectable on a patient-specific prescription. Its federal record is stated on its own terms below.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Iowa’s pharmacy regulators say about compounded medications
Iowa’s distinctive move is codification. Where most states lean on the federal framework implicitly, Iowa’s own administrative code carries the copy standard, the documentation duty, and the shortage exception. That makes the state unusually legible: you can read exactly what an Iowa prescription for a compounded preparation must say.
Iowa Administrative Code rule 657—20.12 permits compounding a preparation that is essentially a copy of an FDA-approved drug only when it is changed to produce a clinically significant difference for an individual patient as determined and authorized by the prescriber, or when the approved drug is currently listed on FDA’s drug shortages database; the prescription must clearly indicate the relevant change, and one identifying only a patient name and formulation is insufficient. Source: Iowa Administrative Code 657—Chapter 20, Compounding Practices.
An out-of-state pharmacy dispensing prescription drugs to Iowa patients must hold a nonresident pharmacy license issued by the Iowa Board of Pharmacy. Source: Iowa Board of Pharmacy.
Iowa permits prescribing on the basis of a telehealth encounter meeting the state’s standard of care; no in-person-first requirement applies to the medication lines on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.
An Iowa order looks like any other OrderlyMeds order: eligibility online, a telehealth evaluation with an Iowa-licensed provider, and fulfillment by a licensed partner pharmacy, with the prescription documentation above handled by the prescriber as part of the visit. Pricing is national: Des Moines pays the posted price.
Iowa availability FAQs
Is compounded semaglutide available in Iowa?
Yes, through licensed partner pharmacies, with the prescription documentation Iowa’s code expects written by your prescriber as part of the evaluation. New customers start at $74/month for two months.
Why would my Iowa prescription mention a clinical difference?
Iowa’s code expects the prescription for a compounded preparation to state what is clinically different for the patient. Your prescriber writes that during the evaluation; the cited section above quotes the requirement.
Which research peptides ship to Iowa?
BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables on patient-specific prescriptions; KPV is not carried. Each line’s federal record is stated above, per substance.
How long does delivery to Iowa take?
Our published window is 8–10 business days from signup.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
